At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml) +1 morebiological
Likely dose
Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents
In Brief
A Phase 3 clinical trial evaluating Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml) and Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml) for Human Influenza. Completed, enrolled 120 participants.
Detailed Summary
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Influenza
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
Primary CompletionDec 2014
First PostedMar 2015
TodayJul 2026
First PostedMar 13, 2015
Enrollment StartOct 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.3 years ago
Interventions
Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)biological
vaccination
Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)biological
vaccination